Scleroderma and Related Disorders

Scleroderma: Intro & Types - Skin Deep & Beyond

• Systemic Sclerosis (SSc): Autoimmune; fibrosis (skin, organs), vascular damage.
• Types:
  • Limited Cutaneous (lcSSc): Skin thickening distal elbows/knees, ± face.
    • 📌 CREST: Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasias.
  • Diffuse Cutaneous (dcSSc): Widespread skin thickening (proximal, trunk); early organ involvement.
  • SSc sine scleroderma: Organ involvement, no skin changes.

⭐ Anti-Scl-70 (topoisomerase I) antibodies: specific for diffuse SSc, associated with ILD (Interstitial Lung Disease).

Pathogenesis Unveiled - Triad Trouble

• Vascular Injury (Endothelial Dysfunction):
  • Earliest event: damage to small blood vessels.
  • ↑ET-1 (vasoconstrictor), ↓NO (vasodilator).
  • Causes intimal proliferation, narrowing, ischemia.
• Immune Activation & Autoimmunity:
  • Aberrant T & B cell activation; cytokine release.
  • Autoantibodies: Anti-Scl-70 (topo I), Anti-centromere (ACA).
  • Key cytokines: TGF-β, IL-4, IL-13, PDGF.
• Fibrosis (Myofibroblast Activation):
  • Fibroblasts transform into myofibroblasts.
  • Excessive collagen & ECM deposition.
  • Progressive tissue hardening, organ dysfunction.

⭐ TGF-β: master regulator of fibrosis, drives myofibroblast differentiation & collagen overproduction.

Clinical Canvas: Systemic Impact - Organ Battlegrounds

• Skin:
  • lcSSc (📌CREST): Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasias.
  • dcSSc: Widespread thickening; "salt-and-pepper" skin; digital ulcers.
• Vascular: Raynaud's (initial), digital ischemia, PAH, Scleroderma Renal Crisis (SRC).
• Lungs: Interstitial Lung Disease (ILD - major mortality), PAH.

  ⭐ NSIP is the most common ILD pattern in Scleroderma, a leading cause of mortality.

• GI Tract: Esophageal dysmotility (GERD), GAVE ("watermelon stomach"), malabsorption.
• Kidneys: SRC (↑BP, ARF) - ACE inhibitors are crucial.
• MSK/Cardiac: Arthralgia, myopathy, tendon rubs (dcSSc); pericarditis, myocardial fibrosis.

Diagnosis & Markers - Detective Work

• ACR/EULAR 2013 Criteria: Score >9 confirms SSc.
  • Key items: Proximal skin thickening, sclerodactyly, Raynaud's, abnormal nailfold capillaries, SSc-specific autoantibodies (ACA, Scl-70, RNA Pol III).
• Key Autoantibodies:
  • Anti-Scl-70 (Topoisomerase I): Diffuse SSc (dcSSc), ↑ILD risk.
  • Anti-Centromere (ACA): Limited SSc (lcSSc), CREST association.
  • Anti-RNA Pol III: dcSSc, ↑renal crisis, malignancy risk.

⭐ Anti-RNA Pol III: Strong predictor for scleroderma renal crisis, especially in early, rapidly progressive dcSSc.

Management & Prognosis - Taming the Tightness

• Core Strategy: Early diagnosis, multidisciplinary care. Aim: symptomatic relief, limit organ damage. No cure exists.

• Key Treatments:
  • Immunosuppressants (MMF, MTX, CYC): For progressive skin/ILD.
  • Vasoactive agents:
    • Raynaud's: CCBs (Nifedipine), PDE5-i.
    • PAH: Bosentan, Sildenafil, prostacyclins.
  • Scleroderma Renal Crisis (SRC): Prompt high-dose ACE inhibitors (e.g., Captopril) are crucial.
• Prognosis: Variable. Poorer with diffuse cutaneous SSc (dcSSc), anti-Scl-70 Ab, and early significant lung, heart, or kidney damage.

⭐ ACE inhibitors are life-saving in Scleroderma Renal Crisis, drastically improving outcomes.

Beyond SSc: Related Syndromes - Mimicry & More

• Eosinophilic Fasciitis: Symmetrical, painful skin induration (spares hands/face); peripheral eosinophilia, "groove sign". Steroid-responsive.
• Scleredema (Buschke): Non-pitting induration (neck, upper back); associated with diabetes, paraproteinemia.
• Scleromyxedema: Generalized waxy papules, monoclonal gammopathy (IgG-lambda), leonine facies.
• Nephrogenic Systemic Fibrosis (NSF): Gadolinium exposure in renal impairment; skin thickening.
• Chronic GVHD: Scleroderma-like skin changes post-HSCT.

⭐ Scleromyxedema is strongly associated with monoclonal gammopathy (IgG-lambda).

High‑Yield Points - ⚡ Biggest Takeaways

• Systemic Sclerosis (Scleroderma): fibrosis of skin and internal organs.
• Limited SSc (lcSSc) often presents as CREST syndrome; associated with Anti-centromere antibodies.
• Diffuse SSc (dcSSc): widespread skin thickening, high risk of Interstitial Lung Disease (ILD) and scleroderma renal crisis.
• Anti-Scl-70 (topoisomerase I) and Anti-RNA polymerase III antibodies are markers for dcSSc.
• Scleroderma renal crisis: abrupt malignant hypertension & renal failure; treat with ACE inhibitors.
• Pulmonary Arterial Hypertension (PAH) is a leading cause of mortality in SSc.